FLOW CYTOMETRIC ANALYSIS OF BENIGN & MALIGNANT TUMORS

流式细胞术免疫分型是一种灵敏的良恶性肿瘤分析技术。我们正在研究该技术的改进及其在不同系统中诊断和测量预后标记物的应用。我们正在研究CLL的流式细胞免疫表型和特异性抗原的表达与形态学、细胞遗传学和临床病程的关系。这项研究的数据可能为这种疾病提供预后指标。我们已经改进了流式细胞术监测患者标本化疗诱导的细胞凋亡的方法，并且已经能够检测特定细胞群中的细胞凋亡。这使我们能够证明特定细胞系对化疗药物的不同敏感性。我们已经启动了一项克隆细胞毒性t细胞群在b细胞瘤患者中出现的研究，以确定预后的重要性以及在最小残留疾病检测中产生的困难。结果，我们发现克隆细胞毒性t细胞增殖在毛细胞白血病中以惊人的频率发生。实验室一直对微小和残留淋巴瘤的检测感兴趣。我们正在使用多参数方法来提高单克隆b细胞群检测的灵敏度。通过轻链检测肿瘤b细胞的抗原表达异常模式（如CD10， CD5, CD23, FMC7，或抗原表达强度异常），我们试图在混合多克隆b细胞中检测到极少数肿瘤b细胞。实验室正在研究各种淋巴瘤亚群的特异性流式细胞术标记物，以提高诊断准确性。流式细胞术实验室正在开发流式细胞术分析方法，以检测EBV基因在研究和临床环境中的表达。

Flow Cytometric immunophenotyping is a sensitive technique for analysis of benign and malignant tumors. We are studying the refinement of this technique and its application to diagnosis and measurement of prognostic markers in different systems. We are studying the flow cytometric immunophenotype of CLL and correlating the expression of specific antigens with morphology, cytogenetics and clinical course. Data from this study may provide prognostic markers for this disease. We have refined methods for flow cytometric monitoring of patient specimens for apoptosis induced by chemotherapy and have been able to detect apoptosis in specific cell populations. This has allowed us to demonstrate different sensitivities of specific cell lineages to chemotherapeutic agents. We have initiated a study of clonal cytotoxic T-cell populations that arise in patients with B-cell neoplasia to determine prognostic importance as well as resulting difficulties in minimal residual disease detection. As a result, we have found that clonal cytotoxic T-cell proliferations occur with surprising frequency in hairy cell leukemia. The laboratory has an ongoing interest in detection of minimal and residual lymphoma. We are using multiparametric approaches to improve the sensitivity of detection of monoclonal B-cell populations. By targeting abnormal patterns of antigen expression (eg CD10, CD5, CD23, FMC7, or abnormal intensity of antigen expression) by neoplastic B-cells in light chain detection, we are attempting to detect very small numbers of neoplastic B-cells among admixed polyclonal B-cells. The laboratory is studying specific Flow Cytometric markers of various lymphoma sub-groups to improve diagnostic accuracy. The Flow Cytometry Laboratory is developing methods for Flow Cytometric analysis to detect EBV gene expression in the research and clinical setting.